drug
Atrial Fibrillation
Preclinicalupdated 6mo agoby Inomagen Therapeutics Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagAtrial Fibrillation13 co-mentions · 6 sources
- tagHematology8 co-mentions · 1 sources
- tagCardiology5 co-mentions · 2 sources
- tagHeart Failure3 co-mentions · 1 sources
- companyBaylor College of Medicine2 co-mentions · 2 sources
- tagAdCom2 co-mentions · 1 sources
- tag510(k) Clearance2 co-mentions · 1 sources
- companyAlfred Health Victoria1 co-mentions · 1 sources
indications
indications
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying Atrial Fibrillation
- N/APULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study
- N/AFrom the Emergency Department Directly to Ablation of Atrial Fibrillation Study
- N/AMobile Health Technology-Enabled AFib Management
- N/ACatheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation
- —The Automated Calculation of AF Cycle Length and Complexity Using a Novel EP Recording System
- —Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm
- N/AThe Impact of Expandable Cryoballoon on Autonomic Control of the Heart
- N/ARESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
News(10)
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 7d ago
- Bayer wins FDA nod for a new kind of blood thinnerSunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.biopharma_dive · 8d ago
- FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a rec…fda_press · 8d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 19d ago
- Next-gen RNAi drugmaker City prices $200M IPOThe offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.biopharma_dive · 1mo ago
- BMS’ Phase 3 win for lung drug clouded by high-dose missA low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…biospace · 1mo ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 1mo ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 1mo ago
- ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plansADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.fiercebiotech · 1mo ago
- Newly formed Jaguar acquires Afib device assets from J&JJaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s AFib device Laminar program for an undisclosed price.fiercebiotech · 2mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that